NovaBiotics has a robust and risk-diversified pipeline of clinical and preclinical product candidates for difficult-to-treat, medically unmet fungal, bacterial and polymicrobial conditions.
The pipeline consists of novel antimicrobial peptides generated from our in-house platform technology and a mini-biologic/small molecule.
NovaBiotics has delivered its clinical stage candidates to the clinic in less than five years from invention/patent priority dates through rational drug design principles versus high-risk screening strategies.
The rapidly microbicidal mechanism of action of NovaBiotics’ drug candidates minimises or negates the chance of drug resistance developing in the target microbes. NovaBiotics compounds also have an excellent safety profile and therapeutic index.